At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Niacinamide Supplementation in Primary Open-angle Glaucoma
In Brief
A clinical study evaluating niacinamide supplementation for Primary Open-Angle Glaucoma (POAG). Completed, enrolled 58 participants across 1 site.
Detailed Summary
Niacinamide is a chemical derivative of niacin, also known as vitamin B3. Through its complex role in the energetic metabolism, it has been evaluated and proven useful in several neurodegenerative disorders, such as Alzheimer's disease. Its effect in glaucoma, an optic nerve disorder related to a high intraocular pressure, is not well defined, and requires more research. The investigators aim to assess the physiological effects of niacinamide on specific markers (e.g., visual field parameters, retinal nerve fibre layer thickness, electrophysiological markers such as the latency of the P2 wave on Flash visually evoked potentials) and on the quality of life in primary glaucoma patients.
Study Details
Timeline
Interventions
Patients will take niacinamide supplementation (500mg) every day for 1 year